Co-Authors
This is a "connection" page, showing publications co-authored by JEROEN POLLET and PETER HOTEZ.
Connection Strength
4.580
-
Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
Score: 0.250
-
Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 Sep 20; 16(9).
Score: 0.245
-
A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses. NPJ Vaccines. 2024 Jul 22; 9(1):132.
Score: 0.243
-
The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
Score: 0.239
-
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines (Basel). 2023 Oct 01; 11(10).
Score: 0.229
-
Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
Score: 0.219
-
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
Score: 0.218
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
Score: 0.208
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. bioRxiv. 2022 Mar 22.
Score: 0.206
-
Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
Score: 0.199
-
SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
Score: 0.193
-
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice. bioRxiv. 2021 Feb 09.
Score: 0.191
-
Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections. Vaccines (Basel). 2019 Sep 20; 7(4).
Score: 0.173
-
Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLoS Pathog. 2018 08; 14(8):e1007273.
Score: 0.161
-
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
Score: 0.156
-
Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
Score: 0.147
-
A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
Score: 0.145
-
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
Score: 0.142
-
Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
Score: 0.059
-
The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 Nov; 17(11):e0011519.
Score: 0.058
-
Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nat Commun. 2023 10 25; 14(1):6769.
Score: 0.058
-
Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells. Curr Res Immunol. 2023; 4:100066.
Score: 0.057
-
The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. bioRxiv. 2023 Jul 12.
Score: 0.056
-
Localized cardiac metabolic trajectories and post-infectious metabolic sequelae in experimental Chagas disease. Res Sq. 2023 Jan 20.
Score: 0.055
-
A novel multi-epitope recombinant protein elicits an antigen-specific CD8+?T cells response in Trypanosoma cruzi-infected mice. Vaccine. 2022 10 26; 40(45):6445-6449.
Score: 0.054
-
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
Score: 0.050
-
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
Score: 0.049
-
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021 06; 1865(6):129893.
Score: 0.048
-
Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep. 2021 02 05; 11(1):3222.
Score: 0.048
-
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
Score: 0.047
-
TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol. 2020 10; 42(10):e12769.
Score: 0.046
-
A method to probe protein structure from UV absorbance spectra. Anal Biochem. 2019 12 15; 587:113450.
Score: 0.043
-
A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2019 05; 13(5):e0007413.
Score: 0.042
-
Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
Score: 0.039
-
Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
Score: 0.038
-
Identification, Characterization, and Structure of Tm16 from Trichuris muris. J Parasitol Res. 2017; 2017:4342789.
Score: 0.037
-
Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis. PLoS Negl Trop Dis. 2017 03; 11(3):e0005374.
Score: 0.036
-
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties. Hum Vaccin Immunother. 2016 07 02; 12(7):1707-20.
Score: 0.034
-
Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum Vaccin Immunother. 2015; 11(6):1474-88.
Score: 0.031
-
Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccin Immunother. 2014; 10(7):1914-25.
Score: 0.029